Spiriva

PreclinicalSmall molecule

Spiriva is one of 62 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

AsthmaActive, not recruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Paracetamol

GSK

Preclinical

1 3

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 4

Atrovent

Boehringer Ingelheim

Preclinical

2 5

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 7

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1 8

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Rhinovirus

UUniversity of Virginia

Preclinical

2 10

FP/SAL

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma3 trials

Specific Use-Result of Spiriva Respimat® in Asthmatics

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03188120·193 enrolled

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Completed·PPearl Therapeutics, Inc.·Phase 2/3·NCT03358147·1,077 enrolled

Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02489981·359 enrolled

Chronic Obstructive Pulmonary Disease3 trials

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02177318·3,588 enrolled

Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02242266·121 enrolled

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02172547·10,821 enrolled

COPD1 trial

Description of the Ability to Learn How to Handle Inhaler Devices in COPD

Completed·UUniversity Hospital, Bordeaux·Phase 4·NCT02813200·24 enrolled

Tics1 trial

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02263976·101 enrolled

Salmeterol1 trial

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02254174·36 enrolled

8 more indications

Scar1 trial

PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03097380·19 enrolled

Clinical Trial1 trial

ANTES B+ Clinical Trial

Terminated·FFundacio Privada Mon Clinic Barcelona·Phase 4·NCT06282861·48 enrolled

Efficacy and Safety1 trial

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00496470·660 enrolled

Function1 trial

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02173769·1,845 enrolled

Treatment1 trial

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

Completed·PPearl Therapeutics, Inc.·Phase 3·NCT02347072·80 enrolled

Bronchiectasis1 trial

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT02546297·90 enrolled

Dyspnea1 trial

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

Completed·LLaval University·Phase 4·NCT02567214·50 enrolled

CAR1 trial

SPIRIVA in Ususal Care

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT00274079·395 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Spiriva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spiriva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spiriva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Spiriva

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma3 trials

Chronic Obstructive Pulmonary Disease3 trials

COPD1 trial

Tics1 trial

Salmeterol1 trial

Scar1 trial

Clinical Trial1 trial

Efficacy and Safety1 trial

Function1 trial

Treatment1 trial

Bronchiectasis1 trial

Dyspnea1 trial

CAR1 trial

References

Drug Info

Quick Facts

Related News